Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
Impel NeuroPharma (NASDAQ: IMPL) will host a live webcast on November 15, 2021, at 8:30 a.m. ET, to discuss its Q3 2021 financial results and provide a business update. The event can be accessed by calling 877-295-2648 (domestic) or 470-495-9487 (international), using conference ID 8366131. The webcast will be available on the company's investor relations website, with a replay and accompanying slides accessible afterward.
- Developing innovative therapies for CNS diseases.
- Trudhesa™ nasal spray approved for migraine treatment.
- None.
SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system (CNS), today announced that management will host a live webcast on Monday, November 15, 2021 at 8:30 a.m. ET to report its third quarter 2021 financial results and provide a business update.
The conference call may be accessed by dialling 877-295-2648 (domestic) or 470-495-9487 (international) and referring to conference ID 8366131. A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the webcast and accompanying slides will be available on the Impel NeuroPharma website following the event.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Investor Relations:
Christina Tartaglia
Stern Investor Relations
Phone: (1) 212-362-1200
Email: christina.tartaglia@sternir.com
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com
FAQ
When will Impel NeuroPharma announce its Q3 2021 financial results?
How can I access the Impel NeuroPharma Q3 results webcast?
What is the focus of Impel NeuroPharma's product development?
What is Trudhesa™?
